

Peter Ferguson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6383964/publications.pdf>

Version: 2024-02-01

67
papers

2,189
citations

304602

22
h-index

233338

45
g-index

69
all docs

69
docs citations

69
times ranked

3781
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Dermoscopic features and screening strategies for the detection of small-diameter melanomas. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 932-941. | 0.6 | 11 |
| 2 | Multioomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. <i>Cancer Cell</i> , 2022, 40, 88-102.e7. | 7.7 | 64 |
| 3 | BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. <i>Pathology</i> , 2022, 54, 6-19. | 0.3 | 3 |
| 4 | Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre. <i>Pathology</i> , 2022, , . | 0.3 | 1 |
| 5 | Neoadjuvant dabrafenib and trametinib (D+T) for stage III melanoma: Long-term results from the NeoCombi trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9580-9580. | 0.8 | 1 |
| 6 | Diagnostic accuracy of pigmented labial macules by in-vivo reflectance confocal microscopy and correlation among techniques. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1151-1160. | 0.6 | 4 |
| 7 | Intranuclear inclusions are a distinguishing morphological feature of renal cell carcinoma with leiomyomatous stroma. <i>Pathology</i> , 2021, 53, 543-545. | 0.3 | 0 |
| 8 | The tumour immune landscape and its implications in cutaneous melanoma. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 529-549. | 1.5 | 21 |
| 9 | Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. <i>Pathology</i> , 2021, 53, 141-156. | 0.3 | 126 |
| 10 | CD8 ⁺ T Cells in Merkel Cell Carcinomas Have a Proinflammatory Profile Prognostic of Patient Survival. <i>Cancer Immunology Research</i> , 2021, 9, 612-623. | 1.6 | 22 |
| 11 | Estimating the potential impact of interventions to reduce over-calling and under-calling of melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1519-1527. | 1.3 | 3 |
| 12 | Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/- Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets. <i>Cancers</i> , 2021, 13, 3186. | 1.7 | 11 |
| 13 | Transplant-associated penile Kaposi sarcoma managed with single agent paclitaxel chemotherapy: a case report. <i>BMC Urology</i> , 2021, 21, 87. | 0.6 | 5 |
| 14 | Complex melanoma of the scalp: Diagnosis and management aided by confocal microscopy. <i>Australasian Journal of Dermatology</i> , 2021, , . | 0.4 | 0 |
| 15 | Basal cell carcinoma of the palm: An unusual presentation of a common tumour. <i>Australasian Journal of Dermatology</i> , 2020, 61, 69-70. | 0.4 | 2 |
| 16 | Molecular Profiling of Noncoding Mutations Distinguishes Nevoid Melanomas From Mitotically Active Nevi in Pregnancy. <i>American Journal of Surgical Pathology</i> , 2020, 44, 357-367. | 2.1 | 10 |
| 17 | Melanoma pathology reporting and staging. <i>Modern Pathology</i> , 2020, 33, 15-24. | 2.9 | 61 |
| 18 | Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. <i>Nature Communications</i> , 2020, 11, 5259. | 5.8 | 102 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | 12. A rare skin rash associated with viral infection in the immunosuppressed: A case of trichodysplasia spinulosa. <i>Pathology</i> , 2020, 52, S137. | 0.3 | 0 |
| 20 | Mutational analysis of undifferentiated melanoma. <i>Pathology</i> , 2020, 52, S63. | 0.3 | 0 |
| 21 | Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma. <i>Cancers</i> , 2020, 12, 3374. | 1.7 | 27 |
| 22 | Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas. <i>Cancer Immunology Research</i> , 2020, 8, 1346-1353. | 1.6 | 13 |
| 23 | Primary dermal melanoma: clinical behaviour, prognosis and treatment. <i>European Journal of Surgical Oncology</i> , 2020, 46, 2131-2139. | 0.5 | 5 |
| 24 | Genomic alterations in metastatic basal cell carcinoma. <i>Pathology</i> , 2020, 52, S63. | 0.3 | 0 |
| 25 | Benign blue naevi involving lymph nodes: A case series with accompanying molecular data and long term follow-up confirms clinical behaviour. <i>Pathology</i> , 2020, 52, S70. | 0.3 | 0 |
| 26 | Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence. <i>Nature Cancer</i> , 2020, 1, 197-209. | 5.7 | 30 |
| 27 | Assessment of the prognostic role of regression in primary cutaneous melanoma. <i>Pathology</i> , 2020, 52, S64. | 0.3 | 0 |
| 28 | Vaccines adjuvanted with an NKT cell agonist induce effective T-cell responses in models of CNS lymphoma. <i>Immunotherapy</i> , 2020, 12, 395-406. | 1.0 | 10 |
| 29 | A phase II study of neoadjuvant pembrolizumab and lenvatinib for resectable stage III melanoma: The neopele study.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS10088-TPS10088. | 0.8 | 2 |
| 30 | Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. <i>Nature Communications</i> , 2019, 10, 3163. | 5.8 | 205 |
| 31 | Journal Watch: our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of melanoma management. <i>Melanoma Management</i> , 2019, 6, MMT18. | 0.1 | 0 |
| 32 | Enhancing T cell responses and tumour immunity by vaccination with peptides conjugated to a weak NKT cell agonist. <i>Organic and Biomolecular Chemistry</i> , 2019, 17, 1225-1237. | 1.5 | 10 |
| 33 | Pembrolizumab for cutaneous squamous cell carcinoma: Report of a case of inoperable squamous cell carcinoma with complete response to pembrolizumab complicated by granulomatous inflammation. <i>JAAD Case Reports</i> , 2019, 5, 491-494. | 0.4 | 13 |
| 34 | Neoadjuvant dabrafenib combined with trametinib for resectable, stage III B ^C , BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 961-971. | 5.1 | 126 |
| 35 | Molecular Genomic Profiling of Melanocytic Nevus. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1762-1768. | 0.3 | 55 |
| 36 | Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer. <i>Oral Oncology</i> , 2019, 92, 33-39. | 0.8 | 43 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility. <i>International Journal of Cancer</i> , 2019, 144, 1049-1060. | 2.3 | 54 |
| 38 | Inter- and inpatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment. <i>Histopathology</i> , 2019, 74, 817-828. | 1.6 | 16 |
| 39 | Correlation Between Surgical and Histologic Margins in Melanoma Wide Excision Specimens. <i>Annals of Surgical Oncology</i> , 2019, 26, 25-32. | 0.7 | 21 |
| 40 | Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. <i>OncImmunity</i> , 2019, 8, e1537581. | 2.1 | 61 |
| 41 | Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities. <i>Journal of Pathology</i> , 2019, 247, 539-551. | 2.1 | 142 |
| 42 | Comprehensive molecular profiling of metastatic melanoma to predict response to monotherapy and combination immunotherapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9511-9511. | 0.8 | 3 |
| 43 | Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas. <i>Oncotarget</i> , 2019, 10, 930-941. | 0.8 | 31 |
| 44 | Improving diagnostic accuracy for suspicious melanocytic skin lesions: New Australian melanoma clinical practice guidelines stress the importance of clinician/pathologist communication. <i>Australian Journal of General Practice</i> , 2019, 48, 357-362. | 0.3 | 9 |
| 45 | Blocking CTLA-4 while priming with a whole cell vaccine reshapes the oligoclonal T cell infiltrate and eradicates tumors in an orthotopic glioma model. <i>OncImmunity</i> , 2018, 7, e1376154. | 2.1 | 22 |
| 46 | HDAC inhibitors restore BRAF inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma. <i>International Journal of Cancer</i> , 2018, 142, 1926-1937. | 2.3 | 48 |
| 47 | Staging of Cutaneous Melanoma. <i>JAMA Network Open</i> , 2018, 1, e180086. | 2.8 | 4 |
| 48 | Melanoma protective antitumor immunity activated by catalytic DNA. <i>Oncogene</i> , 2018, 37, 5115-5126. | 2.6 | 15 |
| 49 | Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. <i>Annals of Oncology</i> , 2018, 29, 1861-1868. | 0.6 | 135 |
| 50 | When is surgery for metastatic melanoma still the most appropriate treatment option?. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 943-945. | 1.1 | 2 |
| 51 | Proteins Annexin A2 and PSA in Prostate Cancer Biopsies Do Not Predict Biochemical Failure. <i>Anticancer Research</i> , 2017, 37, 6943-6946. | 0.5 | 1 |
| 52 | Pleomorphic giant cell carcinoma of the urinary bladder: an extreme form of tumour dedifferentiation. <i>Histopathology</i> , 2016, 68, 533-540. | 1.6 | 35 |
| 53 | ILC2s and T cells cooperate to ensure maintenance of M2 macrophages for lung immunity against hookworms. <i>Nature Communications</i> , 2015, 6, 6970. | 5.8 | 135 |
| 54 | Proteins from formalin-fixed paraffin-embedded prostate cancer sections that predict the risk of metastatic disease. <i>Clinical Proteomics</i> , 2015, 12, 24. | 1.1 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Total submission of pelvic lymphadenectomy tissues removed during radical prostatectomy for prostate cancer increases lymph node yield and detection of micrometastases. <i>Histopathology</i> , 2014, 64, 399-404. | 1.6 | 31 |
| 56 | Effective maybe, but is it cost-effective? A reply. <i>Histopathology</i> , 2014, 65, 729-730. | 1.6 | 2 |
| 57 | A self-adjuvanting vaccine induces cytotoxic T lymphocytes that suppress allergy. <i>Nature Chemical Biology</i> , 2014, 10, 943-949. | 3.9 | 70 |
| 58 | Fever and pancytopenia in a patient with Crohn's disease. <i>Gut</i> , 2013, 62, 1327-1327. | 6.1 | 3 |
| 59 | Using Magnetic Resonance Imaging to Evaluate Dendritic Cell-Based Vaccination. <i>PLoS ONE</i> , 2013, 8, e65318. | 1.1 | 17 |
| 60 | Strongly Magnetic Iron Nanoparticles Improve the Diagnosis of Small Tumours in the Reticuloendothelial System by Magnetic Resonance Imaging. <i>PLoS ONE</i> , 2013, 8, e56572. | 1.1 | 12 |
| 61 | Vaccination with Irradiated Tumor Cells Pulsed with an Adjuvant That Stimulates NKT Cells Is an Effective Treatment for Glioma. <i>Clinical Cancer Research</i> , 2012, 18, 6446-6459. | 3.2 | 47 |
| 62 | Synthesis and Stability of Highly Crystalline and Stable Iron/Iron Oxide Core/Shell Nanoparticles for Biomedical Applications. <i>ChemPlusChem</i> , 2012, 77, 135-140. | 1.3 | 37 |
| 63 | Hot-injection synthesis of iron/iron oxide core/shell nanoparticles for T2 contrast enhancement in magnetic resonance imaging. <i>Chemical Communications</i> , 2011, 47, 9221. | 2.2 | 58 |
| 64 | Simple Synthesis and Functionalization of Iron Nanoparticles for Magnetic Resonance Imaging (<i>Angew. Chem.</i> 18/2011). <i>Angewandte Chemie</i> , 2011, 123, 4110-4110. | 1.6 | 0 |
| 65 | Simple Synthesis and Functionalization of Iron Nanoparticles for Magnetic Resonance Imaging. <i>Angewandte Chemie - International Edition</i> , 2011, 50, 4206-4209. | 7.2 | 148 |
| 66 | Back Cover: Simple Synthesis and Functionalization of Iron Nanoparticles for Magnetic Resonance Imaging (<i>Angew. Chem. Int. Ed.</i> 18/2011). <i>Angewandte Chemie - International Edition</i> , 2011, 50, 4024-4024. | 7.2 | 0 |
| 67 | <i>NRAS</i> and <i>EPHB6</i> mutation rates differ in metastatic melanomas of patients in the North Island versus South Island of New Zealand. <i>Oncotarget</i> , 0, 7, 41017-41030. | 0.8 | 7 |